Case-Based Roundtable Meetings Spotlight March 2021: Hematologic Malignancies

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma

Experts decide whether ruxolitinib is a viable treatment option for steroid-refractory acute graft-versus-host-disease based on the case of a 48-year-old patient.

The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.

"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.

Thomas G. Martin, MD discussed the case of a patient with newly-diagnosed multiple myeloma during a virtual Targeted Oncology Case-Based Roundtable event.